BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18281774)

  • 1. [Two advanced/recurrent breast cancer cases effectively treated by trastuzumab/capecitabine combination therapy].
    Inoue S; Inoue M; Takahashi H; Inoue A; Kunitomo K; Fujii H
    Gan To Kagaku Ryoho; 2008 Feb; 35(2):319-22. PubMed ID: 18281774
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A patient with axillary node metastasis from breast cancer who responded to trastuzumab/capecitabine combination therapy].
    Tokugawa T; Kobayashi A; Matsuyama T; Imai S; Koyama H
    Gan To Kagaku Ryoho; 2009 Mar; 36(3):467-9. PubMed ID: 19295273
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer.
    Wardley AM; Pivot X; Morales-Vasquez F; Zetina LM; de Fátima Dias Gaui M; Reyes DO; Jassem J; Barton C; Button P; Hersberger V; Torres AA
    J Clin Oncol; 2010 Feb; 28(6):976-83. PubMed ID: 20038734
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial.
    Yamamoto D; Iwase S; Kitamura K; Odagiri H; Yamamoto C; Nagumo Y
    Cancer Chemother Pharmacol; 2008 Mar; 61(3):509-14. PubMed ID: 17516068
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of capecitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes.
    Schaller G; Fuchs I; Gonsch T; Weber J; Kleine-Tebbe A; Klare P; Hindenburg HJ; Lakner V; Hinke A; Bangemann N
    J Clin Oncol; 2007 Aug; 25(22):3246-50. PubMed ID: 17577021
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A case of metastatic breast cancer with liver metastasis effectively treated with capecitabine and vinorelbine].
    Inari H; Chiba A; Inaba M; Ino H; Fukahori M; Yoshida A
    Gan To Kagaku Ryoho; 2009 Feb; 36(2):333-5. PubMed ID: 19223759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid tumor shrinkage with lapatinib plus capecitabine in a patient with massive liver involvement.
    Giotta F; Latorre A; Cramarossa A; Simone G; Florio C; Oliva S; Lorusso V
    Tumori; 2013; 99(6):278e-81e. PubMed ID: 24503803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of paclitaxel and trastuzumab-resistant recurrent breast cancer with liver metastasis responding to S-1].
    Nomura T; Sonoo H; Miyake A; Souda M; Yamamoto Y; Shiiki S; Ikeda M; Nakashima K; Tanaka K; Kurebayashi J
    Gan To Kagaku Ryoho; 2008 Sep; 35(9):1607-10. PubMed ID: 18799922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of triple negative recurrent breast cancer successfully treated with capecitabine+docetaxel combination chemotherapy].
    Hachisuka Y; Kamei Y; Umeoka T; Kimura M; Uomoto M; Hatano H; Johira H; Yunoki S; Kawata N; Watanabe R; Ohmori K; Miyata N
    Gan To Kagaku Ryoho; 2008 Mar; 35(3):475-8. PubMed ID: 18347398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [An effective case of liver metastasis of breast cancer treated with capecitabine + docetaxel combination therapy using vitamin B6].
    Umeda T; Abe H; Cho H; Shimizu T; Mori T; Kubota Y; Kawai Y; Tanaka M; Kurumi Y; Tani T
    Gan To Kagaku Ryoho; 2010 Apr; 37(4):687-9. PubMed ID: 20414027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Complete remission of recurrent breast cancer with multiple liver metastases after oral capecitabine and injected trastuzumab.
    Morohashi S; Odagiri H; Morohashi H; Kimura Y; Sasaki M
    Breast Cancer; 2007; 14(3):297-301. PubMed ID: 17690508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function.
    Schüll B; Scheithauer W; Kornek GV
    Onkologie; 2003 Dec; 26(6):578-80. PubMed ID: 14709934
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase II study of a triple combination of oral vinorelbine, capecitabine and trastuzumab as first-line treatment in HER2-positive metastatic breast cancer.
    Chan A; Conte PF; Petruzelka L; Tubiana-Mathieu N; Ganju V; Llombart A; Espie M; Majois F; Gil MG; Vaissiere N; Villanova G
    Anticancer Res; 2013 Jun; 33(6):2657-64. PubMed ID: 23749924
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Case report of advanced breast cancer responding to capecitabine and trastuzumab combination therapy].
    Yoshidome K; Imabun S; Nakahara M; Hiraoka K; Yamagami Y; Tsujimoto M; Nakao K
    Gan To Kagaku Ryoho; 2006 Oct; 33(10):1453-6. PubMed ID: 17033236
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Successful treatment of trastuzumab-resistant HER2-positive breast cancer with extensive liver metastases using the combination of trastuzumab and capecitabine - a case report].
    Shigekawa T; Takeuchi H; Misumi M; Nakamiya N; Sugiyama M; Sugitani I; Fujiuchi N; Osaki A; Saeki T
    Gan To Kagaku Ryoho; 2013 Feb; 40(2):225-7. PubMed ID: 23411960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
    Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
    Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lapatinib plus capecitabine in breast cancer.
    Sonpavde G
    N Engl J Med; 2007 Apr; 356(14):1471; author reply 1471-2. PubMed ID: 17409332
    [No Abstract]   [Full Text] [Related]  

  • 18. Lapatinib in metastatic breast cancer.
    Frenel JS; Bourbouloux E; Berton-Rigaud D; Sadot-Lebouvier S; Zanetti A; Campone M
    Womens Health (Lond); 2009 Nov; 5(6):603-12. PubMed ID: 19863462
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CEREBEL (EGF111438): A Phase III, Randomized, Open-Label Study of Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in Patients With Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer.
    Pivot X; Manikhas A; Żurawski B; Chmielowska E; Karaszewska B; Allerton R; Chan S; Fabi A; Bidoli P; Gori S; Ciruelos E; Dank M; Hornyak L; Margolin S; Nusch A; Parikh R; Nagi F; DeSilvio M; Santillana S; Swaby RF; Semiglazov V
    J Clin Oncol; 2015 May; 33(14):1564-73. PubMed ID: 25605838
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Combination therapy herceptin+xeloda].
    Schaller G
    Onkologie; 2002 Dec; 25 Suppl 5():17-8; discussion 19. PubMed ID: 23573615
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.